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Abstract
Background: The aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients
with Hemodialysis and identify factors associated with these interactions if present.
Methods: The study was an observational- retrospective cohort study that was conducted in ten hemodialysis units
in the West bank, Palestine, between June and August 2015. The data collection form was completed by
interviewing the patients in addition to reviewing their medical records. Potential DDIs were reviewed. SPSS
program was used for data analysis.
Results: The study included 275 patients, a total of 930 potential interactions were identified in 245 (89.1 %) patients.
Patients were prescribed 1–15 drugs with a mean (± SD) of 7.87 ± 2.44, calcium carbonate was the most common
drug prescribed. The most common potential interaction in 114 (41.5 %) patients was Calcium Carbonate/Amlodipine
followed by Calcium Carbonate/Aspirin in 76 (27.6 %) cases. Most patients (89.9 %) of the patients had one or more
comorbid diseases; hypertension, diabetes and gout were the most common. Univariate analysis showed that the
number of potential DDIs were related to the number of diseases, the number of prescribed drugs (P value <0.0001)
and the age of the patient (P value = 0.015). The results of multiple linear regression showed a significant positive
association between number of potential DDIs with the total number of medications (r = 0.242; p < 0.001).
Conclusion: The prevalence of potential drug- drug interactions among hemodialysis patients is very common; they
are highly expected and depend on the number of drugs taken by the patients. Many of these potential interactions
are considered as preventable drug- related problems, so screening for potential interactions and monitoring regularly
is highly needed.
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Background
Chronic Kidney Disease (CKD) is a global public health
concern [1]. End-stage renal disease (ESRD) and CKD
are increasing worldwide [2, 3]. The variation among
communities in the incidence of ESRD mirrors that in
the prevalence of diabetes, obesity, and hypertension [4].
The prevalence of ESRD patients on dialysis in the West
Bank, Palestine is comparable with that of adjacent
countries, but is still far below the high prevalence rate
recorded in Western countries [5].
Patients who go through ESRD and who receive
hemodialysis (HD) are expected to be given 10 to 12
medications daily and many of these medications require
multiple doses each day. Due to poly-pharmacy, frequent
medication adjustments on dialysis versus non- dialysis
days, medically unstable nature of the disease and re-
stricted life styles, these patients are at high risk for de-
veloping drug related problems (DRPs) and non-
adherence. With such a large number of medications,
there is an increased risk for drug-drug interactions
(DDIs) [6], which is associated with significant morbid-
ity, impaired quality of life, mortality, and others such as
primary drivers of hospital admissions and health care
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costs. The specialist must keep in mind that pharma-
ceutical options must be balanced with the potential risk
of multiple medication use. The potential risks include,
but are not limiting to, adverse effects, inappropriate
dosing regimens, drug-disease interactions and drug-
drug interactions [7].
Even though, DDIs are considered as preventable medi-
cation related problems, studies revealed that up to 11 %
of patients experience symptoms associated with DDIs
and these are responsible for approximately 2.8 % of hos-
pital admissions [8]. It is important to remember that rec-
ognizing a potential DDI in a patient, does not mean he
will suffer from an actual DDI and a clinically significant
effect, sometimes extra monitoring is the only action
needed. Monitoring of potential DDIs may improve the
quality of prescribing and dispensing and it might form a
basis for education focused on appropriate prescribing [9].
It is hoped that this study will help raise awareness of the
importance of drug monitoring and review in hemodialysis
patients. Help both clinicians and researchers to have a bet-
ter view on this topic in terms of prevalence and risk fac-
tors and guide clinicians on how to avoid such interactions.
If such interactions can be avoided this will increase the pa-
tients’ quality of life, survival and satisfaction.
The aims of this study are to find the prevalence and
nature of potential drug-drug interactions (DDIs) in pa-
tients with Hemodialysis and identify factors associated
with these interactions if present.
Methods
Study design
An observational- retrospective cohort study was carried
out; it included ESRD patients undergoing hemodialysis
in ten hemodialysis units in the West bank, Palestine,
between June and August 2015. The data collection form
was completed by interviewing the patients in addition
to reviewing their medical records. All hemodialysis pa-
tients who visited the hemodialysis centers in the in-
cluded hospitals during the study period were asked to
participate in this study if they meet the inclusion cri-
teria. The inclusion criteria were as follows: all adult pa-
tients (≥18 years) who were diagnosed as ESRD and
were on maintenance dialysis.
The study protocol was approved by local institutional re-
view boards (IRB) of An -Najah National University and
the Ministry of Health before the beginning of this study.
All subjects had been informed of their rights to refuse or
discontinue participation in the study according to the eth-
ical standards. Informed verbal consent from each eligible
patient was obtained before beginning the interviews.
Sample size
According to the Ministry of Health records of 2013 in
Palestine, the total number of hemodialysis Patients
across ten dialysis units in the West Bank was 800 [10]. An
automated software program, (Raosoft sample size calcula-
tor: (http://www.raosoft.com/samplesize.html) was used to
calculate the required sample size for this study and it was
260 patients. In order to minimize erroneous results and in-
crease the study reliability, the target sample size was in-
creased 5 to 10 %. All of the patients who were asked to
participate in this study accepted to be involved.
Data collection
Patient’s medical records were reviewed and a question-
naire was used. Patient’s age, gender, medical conditions,
all prescribed medications and dosage regimens were
documented from the patient’s charts. The questionnaire
was used to confirm the data obtained from the records
and collect additional data from the patients regarding
sociodemographic characteristics, other medical condi-
tions, prescribed and non- prescribed medications and
herbs. All of the information was tabulated for analysis.
A software program for drug interactions by LexiComp
was used for screening the potential DDIs. According to
this system each interaction was assigned a risk rating of
A, B, C, D, or X. Risk rating A means no known inter-
action, for B no action is needed, C requires to monitor
therapy, D requires to consider therapy modification,
while X means we should avoid combination.
Statistical analysis
Statistical analysis was performed using Statistical Package
for Social Sciences (SPSS version 16.0). Mean ± standard
deviation was computed for continuous data. Frequencies
and percentages were calculated for categorical variables.
Kolmogorov-Smirnov test was used to evaluate the nor-
mal distribution of the variables and Mann-Whitney test
or Kruscal Wallis test was used according to that. Multiple
linear regression was performed also. Probability (p) value
of less than 0.05 was considered to be statistically signifi-
cant for all analyses.
Results
Socio-demographic and clinical characteristics of the
patients
During the study period, a total of 275 patients were
interviewed. Among the surveyed patients, 151 (54.9 %)
were males. The average age (± SD) of patients was
50.67 ± 15.93 years, and the maximum age was 82 years.
Most of the patients 263 (95.6 %) lived with their fam-
ilies. The majority of patients 189 (68.7 %) were living in
a village. Regarding their educational level, a high per-
centage of patients were illiterate or had primary school
only 114 (41.5 %). Most patients 231 (84.0 %) patients
were unemployed, 217 (78.9 %) patients were smokers
and 220 (80.0 %) were married.
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Dialysis data
In this study there was one patient who spent 25 years
on HD. One month was the minimum duration, and
300 months was the maximum. The length of each dia-
lysis session was 210 min in most patients (199; 72.4 %),
other options were 120 in 1 case (0.4 %), 180 in 2 cases
(0.7 %) or 240 in 73 cases (26.5 %). Most patients (218;
79.3 %) had three hemodialysis sessions per week, 54 pa-
tients (19.6 %) were on two sessions per week, 2 patients
(0.7 %) were on 4 sessions per week and one patient
(0.4 %) was on one session per week.
ESRD causes and co-morbid conditions
Many causes can lead to the ESRD, for which HD should
be initiated. A high number of HD patients in this study
had hypertension as cause of ESRD; 85 (30.9 %),
followed by diabetes mellitus in 81 (29.5 %) cases,
followed by unknown causes in 54 (19.6 %) cases, then
polycystic kidney disease in 17 (6.2 %) cases.
Hypertension, diabetes mellitus, gout, myocardial infarc-
tion, hyperlipidemia, and congestive heart failure respect-
ively, were the most commonly co-morbid conditions
present in the HD patients, with different combination be-
tween these conditions in each patient. Among patients,
216 (78.5 %) had hypertension, 117 (42.5 %) had diabetes
mellitus (type 1 & 2), 26 (9.5 %) had gout, 23 (8.4 %) had
myocardial infarction, 17 (6.2 %) had hyperlipidemia, and
16 (5.8 %) had congestive heart failure.
Prescribing pattern of medications in HD patients
During the study period, a total of 90 different medica-
tions were used by the patients. The patients were taking
a minimum of 1 and a maximum of 15 medications,
with a mean (± SD) of 7.87 ± 2.44. The most commonly
prescribed medications were calcium carbonate being
used by 212 (77.1 %). Followed by alfacalcidol, iron/folic
acid, aspirin and amlodipine which were used by 203
(73.8 %), 180 (65.5 %), 151 (54.9 %), 136 (49.5 %) pa-
tients respectively.
Evaluation of potential drug-drug interactions (DDIs)
Among 275 patients, 245 (89.1 %) patients had at least
one potential DDI (Fig. 1). Among the 245 patients who
had potential interactions, a total of 930 interactions
were identified. According to risk rating classification,
676 (72.69 %) were C, 172 (18.49 %) were B, 78 (8.39 %)
were D, and 2 (0.22 %) for each A and X risk rating.
The most common interaction in 114 (41.5 %) patients
was calcium carbonate with amlodipine (Calcium salts
may diminish the therapeutic effect of Calcium Channel
Blockers) followed by aspirin with calcium carbonate in
76 (27.6 %) cases (Antacids may decrease the serum
concentration of Salicylates). Table 1 shows the top ten
potential interactions.
Factors associated with potential drug-drug interactions
Univariate analysis showed a significant correlation be-
tween age and number of potential interactions (p value =
0.015). The number of potential DDIs that the patients
had were also related to the number of chronic diseases
and total number of medications (P value <0.001 for each
one). However, there was no significant relationship with
gender (p value =0.725), smoking status (p value =0.834)
and the duration of dialysis (p value = 0.920) (Table 2).
The results of multiple linear regression showed a signifi-
cant positive association between number of potential
Fig. 1 The frequency of the number of Potential drug-drug interactions
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DDIs with the total number of medications (r = 0.242;
p <0.001). The range of VIF was from 1.067 to 1.206
which indicated absence of multicollinearity between
independent variables (Table 3).
Discussion
The patients in this study had many comorbidities. Hyper-
tension, diabetes mellitus, gout, and myocardial infarction
were the most common co-morbid conditions present in
the HD patients respectively. Regarding the cause, there are
many causes that can lead to the ESRD, for which HD
should be initiated. A high number of HD patients in this
study had hypertension as a cause of ESRD, followed by
diabetes mellitus and polycystic kidney disease. In compari-
son with other studies, in a study from Thailand and an-
other from Latin America, the most common cause of
ESRD was diabetes mellitus [11, 12].
In this study, the 275 HD patients were prescribed 90
different drugs with a mean (± SD) of 7.87 ± 2.44. The
number of medications in this study is close to a Japa-
nese study where the mean was around 7.2 medications
[13]. However, this result is lower than a study in
Malaysia that included ESRD patients where the mean
was around 9 medications [14]. Also, this is lower than a
study from the USA where the mean of medications pre-
scribed for HD patient reached 12.3 ± 0.5 medications
[15]. In summary, polypharmacy is very common in
ESRD patients.
The most commonly prescribed medications in
current study were calcium carbonate, followed by alfa-
calcidol, iron/folic acid, aspirin and amlodipine. When
compared with a study conducted at a nephrology unit
in a Malaysian hospital, the top five used medications
were calcium carbonate (which was the most commonly
prescribed medication also), followed by a combination
of folic acid and vitamin B complex, and the third com-
monly prescribed medication was metoprolol followed
by lovastatin and ferrous sulfate [14]. Another cross-
sectional, observational study was conducted in nephrol-
ogy department of a government hospital in India, the
five most commonly prescribed drugs were multivita-
mins, iron, folic acid, calcium carbonate, and calcitriol
[16]. Due to this poly-pharmacy, HD patients are at
higher risk for drug related problems including DDIs.
In the present study, we found that the prevalence of
potential DDIs in medications of CKD patients was
89.1 %, this is a very high percentage. Another high
prevalence was seen in a study from the India where the
potential DDIs among renal failure patients reached
76.09 % [6]. When actual DDIs were evaluated in a study
performed in U.S by Grabe et al., they accounted for
27.5 % of detected drug related problems [17].
There are different methods that can be used to identify
and classify drug-drug interactions that have been used in
different studies. In current study, LexiComp® was used
for this purpose. Most of the potential DDIs were C-risk
rating which means that monitoring is needed. In 78 po-
tential DDIs detected, therapy modification was required
according to the recommendations as their risk rating was
D. In a prospective, observational study that was carried
out in a South Indian tertiary care hospital, every combin-
ation of prescribed drug was analyzed using the Thomson
Table 1 Top Ten potential drug-drug interactions
NO. Drug-Drug interaction Frequency Risk rating
1. Calcium Carbonate/Amlodipine 114 C
2. Calcium Carbonate/Aspirin 76 B
3. Aspirin/Furosemide 74 C
4. Aspirin/Enoxaparin 40 C
5. Aspirin/Insulin 39 C
6. Calcium Carbonate/Ranitidine 33 B
7. Calcium Carbonate/Atenolol 25 B
8. Amlodipine/Atenolol 21 C
9. Amlodipine/Enalapril 20 C
10. Furosemide/Atenolol 19 C








Male 151 (54.9) 3 (1–5) 0.725a
Female 124 (45.1) 3 (1.25–5)
Age category
<30 40 (14.5) 2 (1–3) 0.015b
30–60 151 (54.9) 3 (1–5)
>60 84 (30.5) 3 (2–5)
Smoker
Yes 58 (21.1) 3 (1–5) 0.834a
No 217 (78.9) 3 (1–5)
Duration of dialysis (years)
<4 203 (73.8) 3 (1–5) 0.920a
≥4 72 (26.2) 3 (2–4)
Total chronic co-morbid disease
None 36 (13.1) 1 (1–3) <0.001b
1 96 (34.9) 2.5 (1–4)
2 90 (32.7) 3 (1.75–5)
≥3 53 (19.3) 4 (2–7)
Total number of medications
<5 26 (9.5) 1 (0.0–1) <0.001a
≥5 249 (90.5) 3 (1–5)
aMann- Whitney test
bKruscal Wallis test
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Reuters Micromedex® DrugReax® system to look for po-
tential DDIs, among the 156 patients, 474 potential drug
interactions were identified. Most of them were delayed in
onset, moderate in severity, pharmacodynamic in nature,
and belong to level 2 i.e., moderate in significance [6]. This
confirms that not in all cases of potential DDIs we need to
stop the combination.
Univariate analysis showed that potential DDIs were
affected by age, number of diseases and drugs. This is
similar to a study from the USA which showed that
older age and number of drugs prescribed were more
likely to lead to major interactions [18]. It is recom-
mended that more attention should be given to patients
with chronic diseases as hypertension and diabetes,
which are considered the most common co-morbidity
among our HD patients, and that all their drugs should
be documented and screened for potential DDIs.
Among different categories of drugs involved in poten-
tial DDIs, most of them were those of daily use to treat
patients with chronic disorders. The most common po-
tential interaction was calcium carbonate with amlodi-
pine, followed by aspirin with calcium carbonate and
then aspirin with furosemide, enoxaparin, and insulin.
However, in another study performed by Rama et al.
(2012), they found that beta blockers, calcium channel
blockers, diuretics, digoxin and antiarrhythmic agents,
were the most common medication involved in the list
of potential DDIs. The most frequently prescribed drug
combinations with potential DDI were ascorbicacid/cya-
nocobalamine, clonidine/metoprolol, amlodipine/meto-
prolol and insulin/metoprolol [6].
Physicians and pharmacists should be more aware of
these potential interactions and they should collaborate to
develop educational programs and improve patients’
counseling to avoid improper use of medications. Further
researches and actual steps are required to optimize pa-
tient outcomes and minimize the prevalence of these in-
teractions. It is important to remember that not all DDIs
are harmful. Some of these combinations can be benefi-
cial. Our recommendation is to give more attention for
patient’s medication list before considering this combin-
ation as desirable or undesirable drug interaction.
The first limitation of this study is that the sampling
method was convenient, that limits the ability to make
broader generalizations from the results. Another limita-
tion is that the honesty of patient to report non
-prescribed drugs and other information was no guaran-
teed. However, this study is the first of its type in
Palestine. These results can give a baseline data that can
be useful in finding the prevalence of potential drug-
drug interactions in patients with ESRD and identify fac-
tors associated with these interactions if present and in
designing and implementing suitable interventions, edu-
cational programs and performing other related studies.
Conclusion
The prevalence of potential drug- drug interactions
among hemodialysis patients is very common; they are
highly expected and depend on the number of drugs
taken by the patients which were used to treat co-
morbid conditions. Many of these interactions are con-
sidered as preventable medication related problems, so
screening for potential interactions and monitoring
regularly should take place routinely before prescribing
any medication to improve quality of prescribing and
dispending.
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